U.S. Transdermal Drug Delivery Markets - Biologics Market Research

U.S. Transdermal Drug Delivery Markets
Frost & Sullivan
August 2, 2006
Pub ID: MC1327283
$6,000.00 Electronic Access - Single User
$7,500.00 Electronic Delivery - Global Site License
$6,500.00 Hard Copy Mail Delivery
Abstract
Countries covered: United States
Research Overview
This Frost & Sullivan research service entitled U.S. Transdermal Drug Delivery Market provides pipeline analysis, forecasts, and technology overviews. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: allergy, osteoporosis, pain management, vaccines, and sexual dysfunction.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this analysis:
Pain Management
Hormone
Central Nervous System
Cardiovascular
Technologies
The following technologies are covered in this research:
Passive Patches
Active Patches
Market Overview
The transdermal drug delivery market is entering a new phase in which pain management is no longer the growth driver for the industry. Diseases and disorders of the central nervous system are providing excellent opportunities for transdermal drug delivery with two new products launched in early 2006. The use of transdermal drug delivery in depression and attention deficit hyperactivity disorder are poised to provide substantial growth for the industry and counteract the loss of patent protection of the largest transdermal drug, Duragesic. A multitude of new products are in development covering all three categories of pain management opioid, non-steroidal anti-inflamatory drugs, and topical pain relief. These new products are expected to provide new therapy options for patients as well as growth of the market.
The transdermal drug delivery market was solely based on passive patch technology that relied on simple diffusion across the skin. With the approval of Synera and IONSYS, active patches utilizing an external energy source are now on the market. Active patches offer a wider array of capabilities allowing for delivery of compounds over 500 daltons and those with challenging physical properties, allowing many companies to develop active patches to deliver pain management drugs, proteins, and vaccines to better control delivery and add value to patients disease management. Passive patch technology is still developing as well, creating smaller patches with better adhesion. These patches continue to control the hormone market and CNS segments with CNS providing the most growth due to entry into new disease indications.